To halt brain diseases, drugs take aim at protein traffic jams that kill neurons
Elie Dolgin • January 16, 2019
Compound that normalizes flow of proteins in cells will now be tested in a clinical trial for ALS
Continue reading at Science Magazine.
Pixels meet paint, as a digital “mask” conceals damage on a 15th-century painting.
Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.